Susquehanna Fundamental Investments, LLC Akebia Therapeutics, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.3 - $0.46 $69,687 - $106,853	-232,291 Reduced 75.04%	77,278 $24,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $617,090 - $911,983	273,049 Added 747.67%	309,569 $700,000
Q3 2021 Nov 15, 2021	SELL	$2.35 - $3.88 $84,788 - $139,990	-36,080 Reduced 49.7%	36,520 $105,000
Q2 2021 Aug 11, 2021	SELL	$2.83 - $4.2 $418,910 - $621,705	-148,025 Reduced 67.09%	72,600 $275,000
Q1 2021 May 17, 2021	BUY	$2.92 - $5.06 $644,225 - $1.12 Million	220,625 New	220,625 $747,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.